186 related articles for article (PubMed ID: 6523344)
1. [Chemotherapy of multiple myeloma].
Estape J; Antón I; Daniels M; Bladé J; Domingo A; Rubio D
Sangre (Barc); 1984; 29(5):936-9. PubMed ID: 6523344
[No Abstract] [Full Text] [Related]
2. [Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].
Monconduit M; Le Loët X; Bernard JF; Menard JF; Grosbois B; Michaux JL; De Gramont A; Laporte JP; Najman A; Jouet JP
Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):477-9. PubMed ID: 3616472
[No Abstract] [Full Text] [Related]
3. The cyclic use of multiple alkylating agents in multiple myeloma.
Harley JB; Ramanan SV; Kim I; Thiagarajan PV; Chen JH; Gomez R; Koppel D; Hyde F; Gustke S; Krall J
W V Med J; 1972 Jan; 68(1):1-3. PubMed ID: 4500402
[No Abstract] [Full Text] [Related]
4. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
[No Abstract] [Full Text] [Related]
5. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results.
Sporn JR; McIntyre OR
Semin Oncol; 1986 Sep; 13(3):318-25. PubMed ID: 3532330
[No Abstract] [Full Text] [Related]
6. Etoposide plus idarubicin and prednisone in refractory or relapsed multiple myeloma. A phase II study.
Capnist G; Chisesi T
Haematologica; 1988; 73(5):431-2. PubMed ID: 3143647
[No Abstract] [Full Text] [Related]
7. Treatment of multiple myeloma in patients with Gaucher disease.
Machaczka M; Lerner R; Klimkowska M; Hägglund H
Am J Hematol; 2009 Oct; 84(10):694-6. PubMed ID: 19743447
[No Abstract] [Full Text] [Related]
8. [Combined cytostatic therapy of plasmacytoma].
Albert P; Zsuzsa M
Orv Hetil; 1977 Jul; 118(31):1855-6. PubMed ID: 887257
[No Abstract] [Full Text] [Related]
9. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
[No Abstract] [Full Text] [Related]
10. [Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)].
Scudla V; Bacovský J; Faltýnek L; Papajík T; Indrák K
Vnitr Lek; 1993 Aug; 39(8):761-8. PubMed ID: 8212624
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory multiple myeloma and considerations for future therapy.
Kyle RA; Greipp PR; Gertz MA
Semin Oncol; 1986 Sep; 13(3):326-33. PubMed ID: 3532331
[No Abstract] [Full Text] [Related]
12. [Chemotherapy of solid tumors as benefit or harm to the patient].
Gröhn P
Duodecim; 1986; 102(22):1662-7. PubMed ID: 3803256
[No Abstract] [Full Text] [Related]
13. [Indications for chemotherapy in multiple myeloma].
Heyll A; Aul C
Dtsch Med Wochenschr; 1996 May; 121(20):675. PubMed ID: 8635404
[No Abstract] [Full Text] [Related]
14. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
15. [Combination chemotherapy in Alkeran-resistant myelomatosis].
Kjølseth I; Wisløff F; Godal HC
Tidsskr Nor Laegeforen; 1984 May; 104(13):873-4. PubMed ID: 6463973
[No Abstract] [Full Text] [Related]
16. Bortezomib plus melphalan and prednisone for multiple myeloma.
Tsubokura M; Kami M; Komatsu T
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
[No Abstract] [Full Text] [Related]
17. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
[No Abstract] [Full Text] [Related]
18. Bortezomib plus melphalan and prednisone for multiple myeloma.
Avvisati G
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
[No Abstract] [Full Text] [Related]
19. Advances in the treatment of elderly patients with multiple myeloma.
Facon T
Clin Adv Hematol Oncol; 2006 Jul; 4(7):501-2. PubMed ID: 17147234
[No Abstract] [Full Text] [Related]
20. [Therapy of multiple myeloma].
La Verde G; Pulsoni A; Petrucci MT; Mandelli F
Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
